Challenges, risks, and opportunities of antiretroviral drugs in women of reproductive potential

References

• World Health Organization. HIV data and statistics. World Health Organization; Jul 2023. Available from: https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/hiv/strategic-information/hiv-data-and-statistics
   Google Scholar
• The path that ends AIDS: uNAIDS global AIDS update 2023. Geneva: Joint United Nations Programme on HIV/AIDS; 2023. Licence: CC BY-NC-SA 3.0 IGO.
   Google Scholar
• Center for Disease Control and Prevention. Estimated HIV incidence and prevalence in the United States, 2015–2019. HIV Surv Supple Rep. 2021;26(1).
   Google Scholar
• Centers for Disease Control. Unexplained immunodeficiency and opportunistic infections in infants–New York, New Jersey, California. MMWR Morb Mortal Wkly Rep. 1982 Dec 17;31(49):665–667.
   Google Scholar
• Lindegren ML, Byers JR, Thomas P, et al. Trends in perinatal transmission of HIV/AIDS in the United States. JAMA J Am Med Ass. 1999;282(6):521–538. doi: 10.1001/jama.282.6.531
   Web of Science ®Google Scholar
• Davis SF, RH B Jr, Lindegren ML, et al. Prevalence and incidence of vertically acquired HIV infection in the United States. JAMA J Am Med Ass. 1995;274(12):952–955. doi: 10.1001/jama.1995.03530120044039
   PubMed Web of Science ®Google Scholar
• Brady MT, Oleske JM, Williams PL, et al. Declines in mortality rates and changes in causes of death in HIV-1-infected children during the HAART era. J Acquir Immune Defic Syndr. 2010 Jan;53(1):86–94.
   PubMed Web of Science ®Google Scholar
• Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS clinical trials group protocol 076 study group. N Engl J Med. 1994;331(18):1173–1180. doi: 10.1056/NEJM199411033311801
   PubMed Web of Science ®Google Scholar
• Joint United Nations programme on HIV/AIDS and the United States President’s emergency plan for AIDS Relief. Start Free Stay Free AIDS Free framework; 2019.
   Google Scholar
• Lampe M, Nesheim S, Oladapo K, et al. Achieving elimination of perinatal HIV in the United States. Pediatrics. 2023;151(4):e2022059604. doi: 10.1542/peds.2022-059604
   PubMedGoogle Scholar
• Nesheim S, Harris LF, Lampe M. Elimination of perinatal HIV infection in the USA and other high-income countries: achievements and challenges. Curr Opin HIV AIDS. 2013;8(5):447–456. doi: 10.1097/COH.0b013e3283636ccb
   PubMed Web of Science ®Google Scholar
• de Ory SJ, Ramos JT, Fortuny C, et al. Sociodemographic changes and trends in the rates of new perinatal HIV diagnoses and transmission in Spain from 1997 to 2015. PLoS One. 2019;14(10):e0223536. doi: 10.1371/journal.pone.0223536
   PubMed Web of Science ®Google Scholar
• Knapp KM. Prevention of mother-to-child human immunodeficiency virus transmission in resource-limited countries. Pediatr Clin North Am. 2022;69(1):1–18. doi: 10.1016/j.pcl.2021.08.007
   PubMed Web of Science ®Google Scholar
• Peters H, Thorne C, Tookey PA, et al. National audit of perinatal HIV infections in the UK, 2006-2013: what lessons can be learnt? HIV Med. 2018;19(4):280–289. doi: 10.1111/hiv.12577
   PubMed Web of Science ®Google Scholar
• Short WR, Anderson JR. Caring for women with HIV: unique needs and challenges. Cleve Clin J Med. 2014;81(11):691–701. doi: 10.3949/ccjm.81a.14009
   PubMed Web of Science ®Google Scholar
• Vella S, Schwartländer B, Sow SP, et al. The history of antiretroviral therapy and of its implementation in resource-limited areas of the world. AIDS. 2012;26(10):1231–1241. doi: 10.1097/QAD.0b013e32835521a3
   PubMed Web of Science ®Google Scholar
• Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. Recommendations for the use of antiretroviral drugs during pregnancy and interventions to reduce perinatal HIV transmission in the United States. Department of Health and Human Services; 2023 [cited 2023 Oct].
   Google Scholar
• World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2nd ed. Geneva: World Health Organization; 2016.
   Google Scholar
• Lindegren ML, Byers JR, Thomas P, et al. Trends in perinatal transmission of HIV/AIDS in the United States. JAMA J Am Med Ass. 1999;282(6):531–538. doi: 10.1001/jama.282.6.531
   PubMed Web of Science ®Google Scholar
• Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet. 1999;354(9181):795–802. doi: 10.1016/S0140-6736(99)80008-7
   PubMed Web of Science ®Google Scholar
• Lallemant M, Le Coeur S, McIntosh K, et al. AZT trial in Thailand. Science. 1995;270(5238):899–900. doi: 10.1126/science.270.5238.899
   PubMed Web of Science ®Google Scholar
• The INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795–807. doi: 10.1056/NEJMoa1506816
   PubMed Web of Science ®Google Scholar
• Cohen MS, Chen YQ, McCauley M, et al. Antiretroviral therapy for the prevention of HIV-1 transmission. N Engl J Med. 2016 Sep 1;375(9):830–839. doi: 10.1056/NEJMoa1600693
   PubMed Web of Science ®Google Scholar
• Joint United Nations Programme on HIV/AIDS (UNAIDS). 90-90-90: an ambitious treatment target to help end the AIDS epidemic. 2014.
   Google Scholar
• Flynn PM, Taha TE, Cababasay M, et al. Prevention of HIV-1 transmission through breastfeeding: efficacy and safety of maternal antiretroviral therapy versus infant nevirapine prophylaxis for duration of breastfeeding in HIV-1-infected women with high CD4 cell count (IMPAACT PROMISE): a randomized, open-label, clinical trial. J Acquir Immune Defic Syndr. 2018;77(4):383–392. doi: 10.1097/QAI.0000000000001612
   PubMed Web of Science ®Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services; 2023 [cited 2023 Oct].
   Google Scholar
• Temprano ANRS Study Group, Danel C, Moh R, et al. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015 Aug 27;373(9):808–822.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Guideline: updates on HIV and infant feeding: the duration of breastfeeding, and support from health services to improve feeding practices among mothers living with HIV. Geneva Switzerland: World Health Organization; 2016.
   Google Scholar
• Centers for disease control and prevention: US Public Health Service: preexposure prophylaxis for the prevention of HIV infection in the United States—2021 update: a clinical practice guideline. Dec 2021.
   Google Scholar
• Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411–422. doi: 10.1056/NEJMoa1202614
   PubMed Web of Science ®Google Scholar
• Peterson L, Taylor D, Roddy R, et al. Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial PLoS clin trial. PLoS Clin Trials. 2007;2(5):e27. doi: 10.1371/journal.pctr.0020027
   PubMedGoogle Scholar
• Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372(6):509–518. doi: 10.1056/NEJMoa1402269
   PubMed Web of Science ®Google Scholar
• Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423–434. doi: 10.1056/NEJMoa1110711
   PubMed Web of Science ®Google Scholar
• Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410. doi: 10.1056/NEJMoa1108524
   PubMed Web of Science ®Google Scholar
• Donnell D, Baeten JM, Bumpus NN, et al. HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr. 2014;66(3):340–348. doi: 10.1097/QAI.0000000000000172
   PubMed Web of Science ®Google Scholar
• Delany-Moretlwe S, Hughes JP, Bock P, et al. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet. 2022;399(10337):1779–1789. doi: 10.1016/S0140-6736(22)00538-4
   PubMed Web of Science ®Google Scholar
• Celum C, Hosek S, Tsholwana M, et al. PrEP uptake, persistence, adherence, and effect of retrospective drug level feedback on PrEP adherence among young women in southern Africa: results from HPTN 082, a randomized controlled trial. PLoS Med. 2021;18(6):e1003670. doi: 10.1371/journal.pmed.1003670
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. PrEP for HIV prevention in the U.S. 2023 Sep 29. Available from: https://www.cdc.gov/nchhstp/newsroom/fact-sheets/hiv/PrEP-for-hiv-prevention-in-the-US-factsheet.html
   Google Scholar
• Crooks N, Singer RB, Smith A, et al. Barriers to PrEP uptake among black female adolescents and emerging adults. Prev Med Rep. 2022;31:102062. doi: 10.1016/j.pmedr.2022.102062
   PubMedGoogle Scholar
• Fields SD, Gruber J, Clue J, et al. Prevalence of renal and bone risk factors among individuals prescribed oral pre-exposure prophylaxis for HIV. IJID Reg. 2023 Jan 11;6:68–75. doi: 10.1016/j.ijregi.2023.01.004
   PubMedGoogle Scholar
• Pilkington V, Hill A, Hughes S, et al. How safe is TDF/FTC as PrEP? A systematic review and meta-analysis of the risk of adverse events in 13 randomised trials of PrEP. J Virus Erad. 2018;4(4):215–224. doi: 10.1016/S2055-6640(20)30312-5
   PubMed Web of Science ®Google Scholar
• Landovitz RJ, Li S, JJ E Jr, et al. Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial. Lancet HIV. 2020;7(7):e472–e481. doi: 10.1016/S2352-3018(20)30106-5
   PubMed Web of Science ®Google Scholar
• Stranix-Chibanda L, Anderson PL, Kacanek D, et al. Tenofovir diphosphate concentrations in dried blood spots from pregnant and postpartum adolescent and young women receiving daily observed pre-exposure prophylaxis in Sub-Saharan Africa. Clinical Infectious Diseases. 2020;73(7):e1893–e1900. doi: 10.1093/cid/ciaa1872
   Web of Science ®Google Scholar
• Hannaford A, Arens Y, Koenig H. Real-time monitoring and point-of-care testing: a review of the Current landscape of PrEP adherence monitoring. Patient Prefer Adherence. 2021;5(15):259–269. doi: 10.2147/PPA.S248696
   Google Scholar
• Delany-Moretlwe S, Hughes J, Guo X, et al. Evaluation of CAB-LA safety and PK in pregnant women in the blinded phase of HPTN 084. Conference on Retroviruses and Opportunistic Infections (CROI); Virtual 2022.
   Google Scholar
• Joseph Davey DL, Pintye J, Baeten JM, et al. Emerging evidence from a systematic review of safety of pre-exposure prophylaxis for pregnant and postpartum women: where are we now and where are we heading. J Int AIDS Soc. 2020;23(1):e25426. doi: 10.1002/jia2.25426
   PubMed Web of Science ®Google Scholar
• Mugo NR, Hong T, Celum C, et al. Pregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: a randomized clinical trial. JAMA. 2014;312(4):362–371. doi: 10.1001/jama.2014.8735
   PubMed Web of Science ®Google Scholar
• Callahan R, Nanda K, Kapiga S, et al. Pregnancy and contraceptive use among women participating in the FEM-PrEP trial. J Acquir Immune Defic Syndr. 2015;68(2):196–203. doi: 10.1097/QAI.0000000000000413
   PubMed Web of Science ®Google Scholar
• Heffron R, Mugo N, Hong T, et al. Pregnancy outcomes and infant growth among babies with in-utero exposure to tenofovir-based preexposure prophylaxis for HIV prevention. AIDS. 2018;32(12):1707–1713. doi: 10.1097/QAD.0000000000001867
   PubMed Web of Science ®Google Scholar
• Pintye J, Kinuthia J, Roberts DA, et al. Brief report: integration of PrEP services into routine antenatal and postnatal care: experiences from an implementation program in Western Kenya. J Acquir Immune Defic Syndr. 2018;29(5):590–595. doi: 10.1097/QAI.0000000000001850
   Google Scholar
• Dettinger JC, Kinuthia J, Pintye J, et al. Perinatal outcomes following maternal pre-exposure prophylaxis (PrEP) use during pregnancy: results from a large PrEP implementation program in Kenya. J Int AIDS Soc. 2019;22(9):e25378. doi: 10.1002/jia2.25378
   PubMed Web of Science ®Google Scholar
• Bunge K, Balkus JE, Fairlie L, et al. DELIVER: a safety study of a dapivirine vaginal ring and oral PrEP for the prevention of HIV during pregnancy. J Acquir Immune Defic Syndr. 2024;95(1):65–73. doi: 10.1097/QAI.0000000000003312
   PubMed Web of Science ®Google Scholar
• Makanani B, Balkus JE, Jiao Y, et al. Pregnancy and infant outcomes among women using the dapivirine vaginal ring in early pregnancy. J Acquir Immune Defic Syndr. 2018;79(5):566–572. doi: 10.1097/QAI.0000000000001861
   PubMed Web of Science ®Google Scholar
• Baeten JM, Palanee-Phillips T, Brown ER, et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N Engl J Med. 2016;375(22):2121–2132. doi: 10.1056/NEJMoa1506110
   PubMed Web of Science ®Google Scholar
• Landovitz RJ, Li S, Grinsztejn B, et al. Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial. PLoS Med. 2018;15(11):e1002690. doi: 10.1371/journal.pmed.1002690
   PubMed Web of Science ®Google Scholar
• Fonner VA, Ridgeway K, van der Straten A, et al. Safety and efficacy of long-acting injectable cabotegravir as preexposure prophylaxis to prevent HIV acquisition. AIDS. 2023 May;37(8):957–966.
   PubMedGoogle Scholar
• Aaron E, Blum C, Seidman D, et al. Optimizing delivery of HIV preexposure prophylaxis for women in the United States. AIDS Patient Care STDS. 2018;31(1):16–23. doi: 10.1089/apc.2017.0201
   Google Scholar
• Calabrese SK, Dovidio JF, Tekeste M, et al. HIV pre-exposure prophylaxis stigma as a multidimensional barrier to uptake among women who attend planned parenthood. J Acquir Immune Defic Syndr. 2018;79(1):46–53. doi: 10.1097/QAI.0000000000001762
   PubMed Web of Science ®Google Scholar
• Kinuthia J, Pintye J, Abuna F, et al. Pre-exposure prophylaxis uptake and early continuation among pregnant and post-partum women within maternal and child health clinics in Kenya: results from an implementation programme. Lancet HIV. 2020;7(1):e38–e48. doi: 10.1016/S2352-3018(19)30335-2
   PubMed Web of Science ®Google Scholar
• Corneli A, Perry B, McKenna K, et al. Participants’ explanations for nonadherence in the FEM-PrEP clinical trial. J Acquir Immune Defic Syndr. 2016;71(4):452–461. doi: 10.1097/QAI.0000000000000880
   PubMed Web of Science ®Google Scholar
• d’Arminio Monforte A, Anderson J, Olczak A. What do we know about antiretroviral treatment of HIV in women? Antivir Ther. 2014;18(2_suppl):27–34. doi: 10.3851/IMP2647
   Google Scholar
• World Health Organization. The world health report: 2004: changing history. 2004.
   Google Scholar
• Kalungwe M, Mbalinda SN, Karonga T, et al. Exploring barriers to antiretroviral therapy adherence among pregnant women: a scoping literature review. Int J Gynaecol Obstet. 2022;159(2):343–350. doi: 10.1002/ijgo.14130
   PubMed Web of Science ®Google Scholar
• Adeniyi OV, Ajayi AI, Ter Goon D, et al. Factors affecting adherence to antiretroviral therapy among pregnant women in the Eastern Cape, South Africa. BMC Infect Dis. 2018;18(1):175. doi: 10.1186/s12879-018-3087-8
   PubMedGoogle Scholar
• Colvin CJ, Konopka S, Chalker JC, et al. A systematic review of health system barriers and enablers for antiretroviral therapy (ART) for HIV-Infected pregnant and postpartum women. PLoS One. 2014;9(10):e108150. doi: 10.1371/journal.pone.0108150
   PubMed Web of Science ®Google Scholar
• Wanga I, Helova A, Abuogi LL, et al. Acceptability of community-based mentor mothers to support HIV-positive pregnant women on antiretroviral treatment in western Kenya: a qualitative study. Bmc Pregnancy Childbirth. 2019;19(288). doi: 10.1186/s12884-019-2419-z
   PubMedGoogle Scholar
• Rendell S, Schmidt H, Neergaard R, et al. Integrating ART adherence support technologies in the care of pregnant and postpartum people with HIV: a qualitative study. Implement Sci Commun. 2022;3(1):85. doi: 10.1186/s43058-022-00331-0
   PubMedGoogle Scholar
• Abrams EJ, Mofenson LM, Pozniak A, et al. Enhanced and timely investigation of ARVs for use in pregnant women. J Acquir Immune Defic Syndr. 2021;86(5):607–615. doi: 10.1097/QAI.0000000000002597
   PubMed Web of Science ®Google Scholar
• Haberl A, R A. How does HIV affect the reproductive choices of women of childbearing age? Antivir Ther. 2013;18(2_suppl):35–44. doi: 10.3851/IMP2638
   PubMedGoogle Scholar
• Colbers A, Mirochnick M, Schalkwijk S, et al. Importance of prospective studies in pregnant and breastfeeding women living with human immunodeficiency virus. Clin Infect Dis. 2019;69(7):1254–1258. doi: 10.1093/cid/ciz121
   PubMed Web of Science ®Google Scholar
• Ofotokum I, Chuck SK, H JE. Antiretroviral pharmacokinetic profile: a review of sex differences. Gender med. 2007;4(2):106–119. doi: 10.1016/S1550-8579(07)80025-8
   PubMedGoogle Scholar
• FDA. Pregnant women: scientific and ethical considerations for inclusion in clinical trials guidance for industry. Rockville (MD): U.S. Department of Health and Human Services Food and Drug Administration; Center for Drug Evaluation and Research (CDER); Center for Biologics Evaluation and Research (CBER); 2018.
   Google Scholar
• IMPAACT P1026S/PK in pregnancy: pharmacokinetic properties of antiretroviral and related drugs during pregnancy and postpartum [Internet]. 2020. Available from: https://www.impaactnetwork.org/studies/p1026s.
   Google Scholar
• IMPAACT 2026: pharmacokinetic properties of antiretroviral and anti-tuberculosis drugs during pregnancy and postpartum [Internet]. 2021. Available from: https://www.impaactnetwork.org/studies/impaact2026.
   Google Scholar
• The PHASES Working Group. Ending the evidence gap for pregnant women around HIV & co-infections: a call to action [internet]. Chapel Hill (NC): 2020 [cited Feb 2024]. Available from: http://hiv.pregnancyethics.org.
   Google Scholar
• Liu XI, Momper JD, Rakhmanina NY, et al. Prediction of maternal and fetal pharmacokinetics of dolutegravir and raltegravir using physiologically based pharmacokinetic modeling. Clin Pharmacokinet. 2020;59(11):1433–1450. doi: 10.1007/s40262-020-00897-9
   PubMed Web of Science ®Google Scholar
• Liu XI, Momper JD, Rakhmanina NY, et al. Physiologically based pharmacokinetic modeling framework to predict neonatal pharmacokinetics of transplacentally acquired emtricitabine, Dolutegravir, and Raltegravir. Clin Pharmacokinet. 2021;60(6):795–809. doi: 10.1007/s40262-020-00977-w
   PubMed Web of Science ®Google Scholar
• Patel K, Huo Y, Jao J, et al. Dolutegravir in pregnancy as compared with Current HIV regimens in the United States. N Engl J Med. 2022;387(9):799–809. doi: 10.1056/NEJMoa2200600
   PubMed Web of Science ®Google Scholar
• Buckoreelall K, Cressey TR, K JR. Pharmacokinetic optimization of antiretroviral therapy in pregnancy. Clin Pharmacokinet. 2012;51(10):639–659. doi: 10.1007/s40262-012-0002-0
   PubMed Web of Science ®Google Scholar
• Bierhoff M, Smolders EJ, Tarning J, et al. Pharmacokinetics of oral tenofovir disoproxil fumarate in pregnancy and lactation: a systematic review. Antivir Ther. 2019;24(7):529–540. doi: 10.3851/IMP3341
   PubMed Web of Science ®Google Scholar
• Best BM, Burchett S, Li H, et al. Pharmacokinetics of tenofovir during pregnancy and postpartum. HIV Med. 2015;16(8):502–511. doi: 10.1111/hiv.12252
   PubMed Web of Science ®Google Scholar
• Bukkems VE, Colbers A, Marzolini C, et al. Drug-drug interactions with antiretroviral drugs in pregnant women living with HIV: are they different from non-pregnant individuals? Clin Pharmacokinet. 2020;59(10):1217–1236. doi: 10.1007/s40262-020-00914-x
   PubMed Web of Science ®Google Scholar
• Guttmacher Institute. Contraceptive use in the United States by method - fact sheet. 2021 May.
   Google Scholar
• Nanda K, Stuart GS, Robinson J, et al. Drug interactions between hormonal contraceptives and antiretrovirals. AIDS. 2017;31(7):917–950. doi: 10.1097/QAD.0000000000001392
   PubMed Web of Science ®Google Scholar
• Tepper NK, Curtis KM, Cox S, et al. Update to U.S. Medical eligibility criteria for contraceptive use, 2016: updated recommendations for the use of contraception among women at high risk for HIV infection. MMWR Morb Mortal Wkly Rep. 2020;69(14):405–410. doi: 10.15585/mmwr.mm6914a3
   PubMed Web of Science ®Google Scholar
• Curtis KM, Tepper NK, Jatlaoui TC, et al. US medical eligibility criteria for contraceptive use, 2016. MMWR Recomm Rep. 2016;65(No. RR–3):1–104. doi: 10.15585/mmwr.rr6503a1
   Web of Science ®Google Scholar
• Thurman AR, Anderson S, Doncel GF. Effects of hormonal contraception on antiretroviral drug metabolism, pharmacokinetics and pharmacodynamics. Am J Reprod Immunol. 2014;71(6):523–530. doi: 10.1111/aji.12210
   PubMed Web of Science ®Google Scholar
• Scarsi KK, Darin KM, Chappell CA, et al. Drug-drug interactions, effectiveness, and safety of hormonal contraceptives in women living with HIV. Drug Saf. 2016;39(11):1053–1072. doi: 10.1007/s40264-016-0452-7
   PubMed Web of Science ®Google Scholar
• Scarsi KK, Darin KM, Nakalema S, et al. Unintended pregnancies observed with combined use of the levonorgestrel contraceptive implant and efavirenz-based antiretroviral therapy: a three-arm pharmacokinetic evaluation over 48 weeks. Clin Infect Dis. 2016 Mar 15;62(6):675–682. doi: 10.1093/cid/civ1001
   PubMed Web of Science ®Google Scholar
• Scarsi KK, Cramer YS, Rosenkranz SL, et al. Antiretroviral therapy and vaginally administered contraceptive hormones: a three-arm, pharmacokinetic study. Lancet HIV. 2019;6(9):e601–e612. doi: 10.1016/S2352-3018(19)30155-9
   PubMed Web of Science ®Google Scholar
• American College of Obstetricians and Gynecologists. ACOG practice bulletin. No. 73: use of hormonal contraception in women with coexisting medical conditions, reaffirmed 2011. Obstet Gynecol. 2006;107(6):1453–1472. doi: 10.1097/00006250-200606000-00055
   PubMedGoogle Scholar
• Scarsi KK, Smeaton LM, Podany AT, et al. Pharmacokinetics of dose-adjusted levonorgestrel emergency contraception combined with efavirenz-based antiretroviral therapy or rifampicin-containing tuberculosis regimens. Contraception. 2023 May;121:109951. doi: 10.1016/j.contraception.2023.109951
   PubMed Web of Science ®Google Scholar
• Francis J, Mngqibisa R, McIlleron H, et al. A semimechanistic pharmacokinetic model for depot medroxyprogesterone acetate and drug-drug interactions with antiretroviral and antituberculosis treatment. Clin Pharmacol Ther. 2021 Oct;110(4):1057–1065.
   PubMed Web of Science ®Google Scholar
• Watts D. Teratogenicity risk of antiretroviral therapy in pregnancy. Curr HIV/AIDS Rep. 4(3):135–140. doi: 10.1007/s11904-007-0020-y
   PubMedGoogle Scholar
• Zash R, Makhema J, Shapiro R. Neural-tube defects with dolutegravir treatment from the time of conception. N Engl J Med. 2018 Sep 6;379(10):979–981. doi: 10.1056/NEJMc1807653
   PubMed Web of Science ®Google Scholar
• Statement on DTG. Potential safety issue affecting women living with HIV using dolutegravir at the time of conception. Geneva: World Health Organization; 2018. Internet.
   Google Scholar
• Zash R, Holmes LB, Diseko M, et al. Update on neural tube defects with antiretroviral exposure in the tsepamo study, Botswana. AIDS. 2022.
   Web of Science ®Google Scholar
• Pereira GFM, Kim A, Jalil EM, et al. Dolutegravir and pregnancy outcomes in women on antiretroviral therapy in Brazil: a retrospective national cohort study. Lancet HIV. 2021;8(1):e33–e41. doi: 10.1016/S2352-3018(20)30268-X
   PubMed Web of Science ®Google Scholar
• Kourtis AP, Zhu W, Lampe MA, et al. Dolutegravir and pregnancy outcomes including neural tube defects in the USA during 2008-20: a national cohort study. Lancet HIV. 2023;10(9):e588–e596. doi: 10.1016/S2352-3018(23)00108-X
   PubMed Web of Science ®Google Scholar
• Fairlie L, Lavies D, Kalk E, et al. Safety surveillance for PrEP in pregnant and breastfeeding women. Front Reprod Health. 2023;5:1221101. doi: 10.3389/frph.2023.1221101
   PubMedGoogle Scholar
• Ailes E, Zhu W, Clark E, et al. Identification of pregnancies and their outcomes in healthcare claims data, 2008–2019: an algorithm. PLoS One. 2023;18(4):accepted. doi: 10.1371/journal.pone.0284893
   Web of Science ®Google Scholar
• Scheuerle A, C D. Clinical review procedures for the antiretroviral pregnancy registry. Pharmacoepidemiol Drug Saf. 2004;13(8):529–536. doi: 10.1002/pds.971
   PubMed Web of Science ®Google Scholar
• Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral pregnancy registry interim report for 1 January 1989 through 31 January 2023. Morrisville (NC): Registry Coordinating Center; 2023.
   Google Scholar
• Van Dyke RB, Chadwick EG, Hazra R, et al. The PHACS SMARTT Study: assessment of the safety of in utero exposure to antiretroviral drugs. Front Immunol. 2016;7:199. doi: 10.3389/fimmu.2016.00199
   PubMed Web of Science ®Google Scholar
• European Collaborative Study T, Mother-to-child transmission of HIV infection. The European collaborative study. The Lancet. 1988 Nov 5;2(8619):1039–1043. PMID: 2903276. doi: 10.1016/S0140-6736(88)90063-3
   PubMedGoogle Scholar
• Lockman S, Brummel SS, Ziemba L, et al. Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomized, controlled, phase 3 trial. Lancet. 2021;397(10281):1276–1292. doi: 10.1016/S0140-6736(21)00314-7
   PubMed Web of Science ®Google Scholar
• Renaud F, Mofenson LM, Bakker C, et al. Surveillance of ARV safety in pregnancy and breastfeeding: towards a new framework. J Int AIDS Soc. 2022;25 Suppl 2(Suppl. 2):e25922. doi: 10.1002/jia2.25922
   PubMedGoogle Scholar
• Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. Lancet. 2013;382(9903):1525–1533. doi: 10.1016/S0140-6736(13)61809-7
   PubMed Web of Science ®Google Scholar
• Chawla A, Wang C, Patton C, et al. A review of long-term toxicity of antiretroviral treatment regimens and implications for an aging population. Infect Dis Ther. 2018;7(2):183–195. doi: 10.1007/s40121-018-0201-6
   PubMed Web of Science ®Google Scholar
• Kourtis AP, Wiener J, Wang L, et al. Tenofovir disoproxil fumarate use during pregnancy and infant bone health: the tenofovir in pregnancy pilot stud. Pediatr Infect Dis J. 2018;37(11):e264–e268. doi: 10.1097/INF.0000000000002152
   PubMed Web of Science ®Google Scholar
• Nabwire F, Prentice A, Hamill MM, et al. Changes in bone mineral density during and after lactation in Ugandan women with HIV on tenofovir-based antiretroviral therapy. J Bone Miner Res. 2020;35(11):2091–2102. doi: 10.1002/jbmr.4121
   PubMed Web of Science ®Google Scholar
• Stranix-Chibanda L, Tierney C, Sebikari D, et al. Impact of postpartum tenofovir-based antiretroviral therapy on bone mineral density in breastfeeding women with HIV enrolled in a randomized clinical trial. PLoS One. 2021;16(2):e0246272. doi: 10.1371/journal.pone.0246272
   PubMed Web of Science ®Google Scholar
• Eke AC, Mirochnick M, Lockman S, et al. Antiretroviral therapy and adverse pregnancy outcomes in people living with HIV. N Engl J Med. 2023;388(4):344–356. doi: 10.1056/NEJMra2212877
   PubMed Web of Science ®Google Scholar
• Thimm MA, Livingston A, Ramroop R, et al. Pregnancy outcomes in pregnant women with HIV on tenofovir disoproxil fumarate (TDF) compared to tenofovir alafenamide (TAF). J AIDS HIV Treat. 2022;4(1):6–13.
   PubMedGoogle Scholar
• Soepnel LM, Norris SA, Schrier VJ, et al. The association between HIV, antiretroviral therapy, and gestational diabetes mellitus. AIDS. 2017 Jan 2;31(1):113–125. doi: 10.1097/QAD.0000000000001277
   PubMed Web of Science ®Google Scholar
• Asif S, Baxevanidi E, Hill A, et al. The predicted risk of adverse pregnancy outcomes as a result of treatment-associated obesity in a hypothetical population receiving tenofovir alafenamide/emtricitabine/dolutegravir, tenofovir disoproxil fumarate/emtricitabine/dolutegravir or tenofovir disoproxil fumarate/emtricitabine/efavirenz. AIDS. 2021 Dec 15;35:S117–S125.
   PubMed Web of Science ®Google Scholar
• Sibiude J, Warszawski J, Tubiana R, et al. Liver enzyme elevation in pregnant women receiving antiretroviral therapy in the ANRS-French perinatal cohort. J Acquir Immune Defic Syndr. 2019;81:83–94. doi: 10.1097/QAI.0000000000001963
   PubMed Web of Science ®Google Scholar
• Sansone M, Sarno L, Saccone G, et al. Risk of preeclampsia in human immunodeficiency virus-infected pregnant women. Obstet Gynecol. 2016;127(6):1027–1032. doi: 10.1097/AOG.0000000000001424
   PubMed Web of Science ®Google Scholar
• Browne JL, Schrier VJMM, Grobbee DE, et al. HIV, antiretroviral therapy, and hypertensive disorders in pregnancy: a systematic review and meta-analysis. J Acquir Immune Defic Syndr. 2015;70(1):91–98. doi: 10.1097/QAI.0000000000000686
   PubMed Web of Science ®Google Scholar
• Premkumar A, Dude AM, Haddad LB, et al. Combined antiretroviral therapy for HIV and the risk of hypertensive disorders of pregnancy: a systematic review. Pregnancy Hypertens. 2019;17:178–190. doi: 10.1016/j.preghy.2019.05.015
   PubMed Web of Science ®Google Scholar
• Venkatesh KK, Morrison L, Tuomala RE, et al. Profile of chronic comorbid conditions and obstetrical complications among pregnant women with human immunodeficiency virus and receiving antiretroviral therapy in the United States. Clin Infect Dis. 2021;73(6):969–978. doi: 10.1093/cid/ciab203
   PubMed Web of Science ®Google Scholar
• Wall KM, Haddad LB, Mehta CC, et al. Miscarriage among women in the United States women’s interagency HIV study, 1994–2017. Am J Obstet Gynecol. 2019;221(4):.e347.1–.e347.13. doi: 10.1016/j.ajog.2019.05.034
   Web of Science ®Google Scholar
• Hoffman RM, Brummel SS, Britto P, et al. Adverse pregnancy outcomes among women who conceive on antiretroviral therapy. Clin Infect Dis. 2019;68:273–279. doi: 10.1093/cid/ciy471
   PubMed Web of Science ®Google Scholar
• Nachega JB, Uthman OA, Mofenson LM, et al. Safety of tenofovir disoproxil fumarate-based antiretroviral therapy regimens in pregnancy for HIV-infected women and their infants: a systematic review and meta-analysis. J Acquir Immune Defic Syndr. 2017;76(1):1–12. doi: 10.1097/QAI.0000000000001359
   PubMed Web of Science ®Google Scholar
• Jiang W, Ronen K, Osborn L, et al. Predictors of adverse pregnancy outcomes among Kenyan women with HIV on antiretroviral treatment in pregnancy. AIDS. 2022;36(7):1007–1019. doi: 10.1097/QAD.0000000000003215
   PubMed Web of Science ®Google Scholar
• Cowdell I, Beck K, Portwood C, et al. Adverse perinatal outcomes associated with protease inhibitor-based antiretroviral therapy in pregnant women living with HIV: a systematic review and meta-analysis. EClinicalMedicine. 2022;46:101368. doi: 10.1016/j.eclinm.2022.101368
   PubMedGoogle Scholar
• Powis KM, Kitch D, Ogwu A, et al. Increased risk of preterm delivery among HIV-infected women randomized to protease versus nucleoside reverse transcriptase inhibitor-based HAART during pregnancy. J Infect Dis. 2011;204:506–514. doi: 10.1093/infdis/jir307
   PubMed Web of Science ®Google Scholar
• Tshivuila-Matala COO, Honeyman S, Nesbitt C, et al. Adverse perinatal outcomes associated with antiretroviral therapy regimens: systematic review and network metaanalysis. AIDS. 2020;34(1643–56):1643–1656. doi: 10.1097/QAD.0000000000002593
   PubMedGoogle Scholar
• Koss CA, Natureeba P, Plenty A, et al. Risk factors for preterm birth among HIV-infected pregnant Ugandan women randomized to lopinavir/ritonavir- or efavirenz-based antiretroviral therapy. J Acquir Immune Defic Syndr. 2014;67:128–135. doi: 10.1097/QAI.0000000000000281
   PubMed Web of Science ®Google Scholar
• Saleska JL, Turner AN, Maierhofer C, et al. Use of antiretroviral therapy during pregnancy and adverse birth outcomes among women living with HIV-1 in low- and middle-income countries: a systematic review. J Acquir Immune Defic Syndr. 2018;79(1):1–9. doi: 10.1097/QAI.0000000000001770
   PubMed Web of Science ®Google Scholar
• Ikumi NM, Malaba TR, Pillay K, et al. Differential impact of antiretroviral therapy initiated before or during pregnancy on placenta pathology in HIV-positive women. AIDS. 2021;35(5):717–726. doi: 10.1097/QAD.0000000000002824
   PubMed Web of Science ®Google Scholar